Last mentioned: Mar 24, 2026
NDA Submission
Anticipated filing of the New Drug Application with the NMPA.
Primary Endpoint Met
Innovent announces positive top-line results from the Phase 3 STAR study.
STAR Study Initiation
Commencement of the Phase 3 registration trial across multiple sites in China.
Phase 2 Completion
Phase 2 data showed promising safety and efficacy in nAMD patients.
Innovent Biologics' IBI302 (efdamrofusp alfa) successfully met its primary endpoint in the Phase 3 STAR registration trial for neovascular age-related macular degeneration. As the first domestically developed extended-interval treatment in China, it represents a significant shift toward reducing the injection burden for millions of patients.
This page surfaces every story mentioning Innovent Biologics across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Innovent Biologics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |